Treatment of CLL, the most common leukemia in the West, has undergone a revolution in the past few years with the development of agents that target signaling kinases and cell-survival mediators. Survival even among patients with a poor prognosis now exceeds 8 years.
No takes yet. Share an insight, caveat, or question.
Jan A. Burger (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: